SCHEMBL4581478

SCHEMBL4581478

O=[C]c1cnccc1C(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
KDM4C Q9H3R0 4/20 0.45
KDM4D Q6B0I6 2/20 0.45
AKR1C3 P42330 1/20 0.43
ALDH1A1 P00352 4/20 0.42
GAA P10253 2/20 0.42
APP P05067 1/20 0.42
HCAR3 P49019 1/20 0.42
HCAR2 Q8TDS4 1/20 0.42
MAPT P10636 2/20 0.41
PLOD2 O00469 2/20 0.40
KDM4E B2RXH2 1/20 0.40
KDM6B O15054 1/20 0.40
KDM4A O75164 1/20 0.40
THRB P10828 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HPGDS O60760 1/20 0.40
PLOD3 O60568 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8060987 0.89 ALDH1A1 (0.49) KMT2AMEN1ALDH1A1GAAAPP
SCHEMBL64069 0.78 AKR1C3 (0.57) KMT2AMEN1AKR1C3ALDH1A1GAA
SCHEMBL1331831 0.78 AKR1C3 (0.57) KMT2AMEN1AKR1C3ALDH1A1GAA
SCHEMBL7850570 0.77 AKR1C3 (0.62) KMT2AMEN1KDM4CKDM4DAKR1C3
SCHEMBL7824045 0.77 AKR1C3 (0.62) KMT2AMEN1KDM4CKDM4DAKR1C3
SCHEMBL5700207 0.76 KMT2A (0.55) KMT2AMEN1KDM4CKDM4DAKR1C3
SCHEMBL1643213 0.76 ALDH1A1 (0.65) KMT2AMEN1KDM4CKDM4DAKR1C3
SCHEMBL20385461 0.76 KMT2A (0.55) KMT2AMEN1KDM4CKDM4DAKR1C3
SCHEMBL8693095 0.76 KMT2A (0.55) KMT2AMEN1KDM4CKDM4DAKR1C3
SCHEMBL7621095 0.76 KMT2A (0.46) KMT2AMEN1KDM4CKDM4DALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287428-A1 Novel Heterocyclidene Acetamide Derivative MOCHIDA PHARMACEUTICAL CO.,LTD (JP) 2008-11-20 US disclosed
US-4617187-A USING COENZYME Q10; SKING DISORDERS EISAI CO., LTD. (JP) 1986-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287428-A1 Novel Heterocyclidene Acetamide Derivative TRPV1, TRPV3, TRPA1 KMT2A 3094/4885MEN1 4073/4885KDM4C 4322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.